MX375724B - Compuestos y métodos para la inhibición de jak. - Google Patents

Compuestos y métodos para la inhibición de jak.

Info

Publication number
MX375724B
MX375724B MX2018003590A MX2018003590A MX375724B MX 375724 B MX375724 B MX 375724B MX 2018003590 A MX2018003590 A MX 2018003590A MX 2018003590 A MX2018003590 A MX 2018003590A MX 375724 B MX375724 B MX 375724B
Authority
MX
Mexico
Prior art keywords
sup
sub
methyl
compounds
ethyl
Prior art date
Application number
MX2018003590A
Other languages
English (en)
Spanish (es)
Other versions
MX2018003590A (es
Inventor
Birgitta Margareta Åstrand Annika
Cluadio Edmundo Chuaqui
Dedong Wu
James Mccabe
Jason Grant Kettle
Jon James Winter-Holt
Linette Lys Ruston
Magnus K Nilsson
Melissa Marie Vasbinder
Neil Patrick Grimster
Qibin Su
Richard Donald Woessner
Sameer Kawatkar
Tudor Grecu
Wenzhan Yang
Original Assignee
Dizal Jiangsu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dizal Jiangsu Pharmaceutical Co Ltd filed Critical Dizal Jiangsu Pharmaceutical Co Ltd
Publication of MX2018003590A publication Critical patent/MX2018003590A/es
Publication of MX375724B publication Critical patent/MX375724B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2018003590A 2015-09-25 2016-09-22 Compuestos y métodos para la inhibición de jak. MX375724B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562232629P 2015-09-25 2015-09-25
PCT/EP2016/072616 WO2017050938A1 (en) 2015-09-25 2016-09-22 Compounds and methods for inhibiting jak

Publications (2)

Publication Number Publication Date
MX2018003590A MX2018003590A (es) 2018-11-29
MX375724B true MX375724B (es) 2025-03-06

Family

ID=56979589

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003590A MX375724B (es) 2015-09-25 2016-09-22 Compuestos y métodos para la inhibición de jak.

Country Status (17)

Country Link
US (5) US9714236B2 (enExample)
EP (2) EP3353168B1 (enExample)
JP (1) JP6767491B2 (enExample)
KR (2) KR102774784B1 (enExample)
CN (4) CN111606893B (enExample)
AR (1) AR106138A1 (enExample)
AU (1) AU2016328764B2 (enExample)
BR (1) BR112018005833B1 (enExample)
CA (1) CA2995430C (enExample)
DK (1) DK3353168T3 (enExample)
ES (1) ES2956642T3 (enExample)
MX (1) MX375724B (enExample)
PT (1) PT3353168T (enExample)
RU (1) RU2760359C2 (enExample)
TW (1) TWI740843B (enExample)
WO (1) WO2017050938A1 (enExample)
ZA (1) ZA201800782B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102774784B1 (ko) * 2015-09-25 2025-02-27 디잘 (지앙수) 파마슈티칼 씨오., 리미티드 Jak를 억제하기 위한 화합물 및 방법
CN109311858B (zh) 2016-05-26 2021-12-03 里科瑞尔姆Ip控股有限责任公司 Egfr抑制剂化合物
PE20191108A1 (es) 2017-01-17 2019-08-26 Astrazeneca Ab Inhibidores selectivos de jak1
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
US11149029B2 (en) * 2018-07-18 2021-10-19 Astrazeneca Ab Salts of IJAK inhibitors and methods of using the same
EP3854793A4 (en) * 2018-09-21 2022-06-01 Shanghai Ennovabio Pharmaceuticals Co., Ltd. AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY
KR102195348B1 (ko) * 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
AU2020258619C1 (en) * 2019-04-19 2026-01-29 Dizal (Jiangsu) Pharmaceutical Co., Ltd. JAK1 selective kinase inhibitor
CN110627775B (zh) * 2019-10-24 2026-01-30 特科罗生物科技(成都)有限公司 一种小分子化合物
CN111961037B (zh) * 2020-09-17 2021-09-21 嘉兴特科罗生物科技有限公司 一种作为jak激酶抑制剂的药物化合物
WO2022111499A1 (zh) 2020-11-26 2022-06-02 深圳铂立健医药有限公司 一种酰胺化合物、药物组合物及其应用
EP4297873A1 (en) * 2021-02-26 2024-01-03 Tyra Biosciences, Inc. Aminopyrimidine compounds and methods of their use
US12390451B2 (en) 2021-03-11 2025-08-19 Janssen Pharmaceutica Nv Small molecule inhibitor of the JAK family of kinases
CN115260128B (zh) * 2022-09-21 2022-12-09 苏州凯瑞医药科技有限公司 一种新型jak抑制剂关键中间体的制备方法
WO2025230951A1 (en) * 2024-04-29 2025-11-06 Icahn School Of Medicine At Mount Sinai Method of treating adenoid cystic carcinoma

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2364340T3 (es) 2004-03-30 2011-08-31 Vertex Pharmaceuticals Incorporated Azaindoles útiles como inhibidores de jak y otras proteína quinasas.
GB0500492D0 (en) * 2005-01-11 2005-02-16 Cyclacel Ltd Compound
BRPI0618011A2 (pt) 2005-10-28 2011-08-16 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito anti-proliferativo e um efeito pró-apoptósico em um animal de sangue quente, para tratar doença e para produzir um efeito inibidor de jak em um animal de sangue quente
EA200870217A1 (ru) * 2006-01-30 2009-02-27 Экселиксис, Инк. 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
JP5208123B2 (ja) * 2006-12-08 2013-06-12 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
KR101705158B1 (ko) * 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Egfr 억제제 및 질환 치료방법
NZ596479A (en) 2009-05-22 2014-01-31 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
US20130225615A1 (en) * 2010-09-01 2013-08-29 Ambit Biosciences Corporation 2-cycloquinazoline derivatives and methods of use thereof
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
AU2011328237A1 (en) * 2010-11-09 2013-05-23 Cellzome Limited Pyridine compounds and aza analogues thereof as TYK2 inhibitors
CA2818542A1 (en) * 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2012116247A1 (en) 2011-02-25 2012-08-30 Synta Pharmaceuticals Corp. Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers
US8691807B2 (en) * 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
DK2830662T3 (da) 2012-03-29 2019-01-02 Univ Columbia Fremgangsmåder til behandlng af hårtabsforstyrrelser
KR102774784B1 (ko) * 2015-09-25 2025-02-27 디잘 (지앙수) 파마슈티칼 씨오., 리미티드 Jak를 억제하기 위한 화합물 및 방법

Also Published As

Publication number Publication date
CN111848586B (zh) 2024-05-03
US20170088543A1 (en) 2017-03-30
MX2018003590A (es) 2018-11-29
CN111606893A (zh) 2020-09-01
RU2760359C2 (ru) 2021-11-24
EP3353168A1 (en) 2018-08-01
CN111606893B (zh) 2021-05-04
EP3353168B1 (en) 2023-08-30
TWI740843B (zh) 2021-10-01
US10654835B2 (en) 2020-05-19
RU2018112993A (ru) 2019-10-28
US12319670B2 (en) 2025-06-03
RU2018112993A3 (enExample) 2020-01-30
US20210078981A1 (en) 2021-03-18
JP6767491B2 (ja) 2020-10-14
AU2016328764B2 (en) 2020-07-09
US20190092760A1 (en) 2019-03-28
BR112018005833B1 (pt) 2023-10-10
AR106138A1 (es) 2017-12-13
DK3353168T3 (da) 2023-10-02
CA2995430A1 (en) 2017-03-30
CA2995430C (en) 2023-07-11
HK1259422A1 (zh) 2019-11-29
US20220119372A1 (en) 2022-04-21
AU2016328764A1 (en) 2018-02-22
PT3353168T (pt) 2023-09-20
CN108368091B (zh) 2020-08-11
KR20250035597A (ko) 2025-03-12
KR20180058719A (ko) 2018-06-01
JP2018529770A (ja) 2018-10-11
US20170320857A1 (en) 2017-11-09
ZA201800782B (en) 2018-12-19
US11247983B2 (en) 2022-02-15
KR102774784B1 (ko) 2025-02-27
BR112018005833A2 (pt) 2018-10-16
CN108368091A (zh) 2018-08-03
US10167276B2 (en) 2019-01-01
CN111646980A (zh) 2020-09-11
US9714236B2 (en) 2017-07-25
CN111646980B (zh) 2021-08-27
WO2017050938A1 (en) 2017-03-30
CN111848586A (zh) 2020-10-30
TW201730186A (zh) 2017-09-01
EP4219482A1 (en) 2023-08-02
ES2956642T3 (es) 2023-12-26

Similar Documents

Publication Publication Date Title
MX2020001235A (es) Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona.
MX2013012776A (es) Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina.
PH12019501639B1 (en) Jak1 selective inhibitors
CY1122279T1 (el) Ενωσεις ναφθυριδινης αναστολεις κινασης jak
MX2020009372A (es) 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas.
MX386103B (es) Inhibidores de mcl-1 y metodos de uso de los mismos.
CY1124173T1 (el) Υποκατεστημενες ενωσεις αμινοπουρινης, συνθεσεις αυτων και μεθοδοι θεραπειας με αυτες
EA201691302A1 (ru) Новые гетероциклические соединения
WO2014031438A3 (en) SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
PH12017500276A1 (en) Aminopyrimidinyl compounds as jak inhibitors
EA201792214A1 (ru) Соединения замещенного хиназолина
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
WO2016105528A3 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2018044767A3 (en) Aminopyrimidines as alk inhibitors
AU2018253590A1 (en) Imidazopyridazine compounds
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
MX2018003590A (es) Compuestos y metodos para la inhibicion de jak.
EP4249071A3 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
RU2018113718A (ru) Новые соединения
MX2021012096A (es) Compuestos de indenilo, composiciones farmaceuticas y usos medicos del mismo.
PH12020551343A1 (en) 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
EA201792320A1 (ru) Способ лечения рака ингибитором пути stat3 и ингибитором киназы
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
TN2016000459A1 (en) Cycloalkyl-linked diheterocycle derivatives.
EA201792087A1 (ru) ПРОИЗВОДНЫЕ 7-(МОРФОЛИН-4-ИЛ)ПИРАЗОЛО[1,5-a]ПИРИМИДИНА, ПРИГОДНЫЕ ДЛЯ ЛЕЧЕНИЯ ИММУННЫХ ИЛИ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ИЛИ РАКА

Legal Events

Date Code Title Description
FG Grant or registration